Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B3eaef4e070b8f9b757f96347ef1bc9e0> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B3eaef4e070b8f9b757f96347ef1bc9e0 NCIT_P378 "NCI" @default.
- B3eaef4e070b8f9b757f96347ef1bc9e0 type Axiom @default.
- B3eaef4e070b8f9b757f96347ef1bc9e0 annotatedProperty IAO_0000115 @default.
- B3eaef4e070b8f9b757f96347ef1bc9e0 annotatedSource NCIT_C175603 @default.
- B3eaef4e070b8f9b757f96347ef1bc9e0 annotatedTarget "A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody ZL-1201 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate." @default.